Corrigendum to “In vitro permeability of silver nanoparticles through porcine oromucosal membrane” (In vitro permeability of silver nanoparticles through porcine oromucosal membrane (2015) 132 (10–16), (S0927776515002805), (10.1016/j.colsurfb.2015.04.061));In vitro permeability of silver nanoparticles through porcine oromucosal membrane

Colloids and Surfaces B: Biointerfaces

Volumn 132, Issue , 2015, Pages 10-16

  Mauro, Marcella ^a   Crosera, Matteo ^a   Bianco, Carlotta ^a   Bellomo, Francesca ^a   Bovenzi, Massimo ^a   Adami, Gianpiero ^a   Larese Filon, Francesca ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Franz cells; In vitro; Mucosal membrane; Permeation; Silver nanoparticles

Indexed keywords

METAL NANOPARTICLES; PERMEATION; RISK ASSESSMENT;

BUCCAL MUCOSA; FOOD INDUSTRIES; FRANZ CELL; FRANZ DIFFUSION CELLS; IN-VITRO; ORAL MUCOSA; SILVER NANOPARTICLES (AGNPS);

SILVER NANOPARTICLES;

SILVER NANOPARTICLE; COLLOID; METAL NANOPARTICLE; SILVER;

ABSORPTION; ANIMAL TISSUE; ARTICLE; CHEEK MUCOSA; CONTROLLED STUDY; DISPERSION; IN VITRO STUDY; MEMBRANE PERMEABILITY; NONHUMAN; PARTICLE SIZE; PHYSICAL PARAMETERS; PIG; POLIDISPERSITY INDEX; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; CHEMISTRY; COLLOID; METABOLISM; MOUTH MUCOSA; PERMEABILITY;

SUS;

ANIMALS; COLLOIDS; IN VITRO TECHNIQUES; METAL NANOPARTICLES; MOUTH MUCOSA; PERMEABILITY; SILVER; SWINE;

EID: 84929579291     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2019.110665     Document Type: Erratum

References (51)

1. Kim Y.S., Song M.Y., Park J.D., Song K.S., Ryu H.R., Chung Y.H., Chang H.K., Lee J.H., Oh K.H., Kelman B.J., Hwang I.K., Yu I.J. Subchronic oral toxicity of silver nanoparticles. Part. Fibre Toxicol. 2010, 6(7):20. 10.1186/1743-8977-7-20.
2. Hadrup N., Loeschner K., Bergström A., Wilcks A., Gao X., Vogel U., Frandsen H.L., Larsen E.H., Lam H.R., Mortensen A. Subacute oral toxicity investigation of nanoparticulate and ionic silver in rats. Arch. Toxicol. 2012, 86(4):543-551.
3. Collart D., Mehrabi S., Robinson L., Kepner B., Mintz E.A. Efficacy of oligodynamic metals in the control of bacteria growth in humidifier water tanks and mist droplets. J. Water Health 2006, 4(2):149-156.
4. Bouwmeester H., Dekkers S., Noordam M.Y., Hagens W.I., Bulder A.S., de Heer C., ten Voorde S.E., Wijnhoven S.W., Marvin H.J., Sips A.J. Review of health safety aspects of nanotechnologies in food production. Regul. Toxicol. Pharmacol. 2009, 53(1):52-62.
5. Chang A.L., Khosravi V., Egbert B. A case of argyria after colloidal silver ingestion. J. Cutan. Pathol. 2006, 33(12):809-811.
6. Johnston H.J., Hutchison G., Christensen F.M., Peters S., Hankin S., Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit. Rev. Toxicol. 2010, 40(4):328-346.
7. Trop M., Novak M., Rodl S., Hellbom B., Kroell W., Goessler W. Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J. Trauma 2006, 60(3):648-652.
8. "ToxFAQs™ for Silver". Agency for Toxic Substances and Disease Registry. Retrieved January 2013.
9. Brandt D., Park B., Hoang M., Jacobe H.T. Argyria secondary to ingestion of homemade silver solution. J. Am. Acad. Dermatol. 2005, 53(2 Suppl. 1):S105-S107.
10. Stepien K.M., Morris R., Brown S., Taylor A., Morgan L. Unintentional silver intoxication following self-medication: an unusual case of corticobasal degeneration. Ann. Clin. Biochem. 2009, 46(Pt 6):520-522.
11. Harris D., Robinson J.R. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 1992, 81(1):1-10.
12. Wertz P.W., Squier C.A. Cellular and molecular basis of barrier function in oral epithelium. Crit. Rev. Ther. Drug Carrier Syst. 1991, 8(3):237-269. (review).
13. Lesch C.A., Squier C.A., Cruchley A., Williams D.M., Speight P. The permeability of human oral mucosa and skin to water. J. Dent. Res. 1989, 68(9):1345-1349.
14. Fox C.L., Modak S.M. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob. Agents Chemother. 1974, 5(6):582-588.
15. Gandhi R.E., Robinson J.R. Bioadhesion in drug delivery. Ind. J. Pharm. Sci. 1988, 50:145-152.
16. Roblegg E., Fröhlich E., Meindl C., Teubl B., Zaversky M., Zimmer A. Evaluation of a physiological in vitro system to study the transport of nanoparticles through the buccal mucosa. Nanotoxicology 2012, 6(4):399-413.
17. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 2001, 81(4):1930-1937.
18. Teubl B.J., Meindl C., Eitzlmayr A., Zimmer A., Fröhlich E., Roblegg E. In-vitro permeability of neutral polystyrene particles via buccal mucosa. Small 2013, 9(3):457-466.
19. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. U S A 2010, 107(2):598-603.
20. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., Fries L. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006, 24(3):254-262.
21. Smith J.H., Brooks P., Johnson S., Tompkins S.M., Custer K.M., Haas D.L., Mair R., Papania M., Tripp R.A. Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine 2011, 29(14):2568-2575.
22. Smith J.H., Papania M., Knaus D., Brooks P., Haas D.L., Mair R., Barry J., Tompkins S.M., Tripp R.A. Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose. Vaccine 2012, 30(19):3026-3033.
23. Li A.V., Moon J.J., Abraham W., Suh H., Elkhader J., Seidman M.A., Yen M., Im E.J., Foley M.H., Barouch D.H., Irvine D.J. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 2013, 5(204). 204ra130.
24. Edetox, 2000. Evaluations and Predictions of Dermal Absorption of Toxic Chemicals, EU Framework V: Quality of Life, Environment and Health Key Action Funding (Project Number: QLKA-2000-00196).
25. Larese F.F., D'Agostin F., Crosera M., Adami G., Renzi N., Bovenzi M., Maina G. Human skin penetration of silver nanoparticles through intact and damaged skin. Toxicology 2009, 255(1-2):33-37.
26. Filon F.L., Crosera M., Adami G., Bovenzi M., Rossi F., Maina G. Human skin penetration of gold nanoparticles through intact and damaged skin. Nanotoxicology 2011, 5(4):493-501.
27. Larese Filon F1, Crosera M., Timeus E., Adami G., Bovenzi M., Ponti J., Maina G. Human skin penetration of cobalt nanoparticles through intact and damaged skin. Toxicol. In Vitro 2013, 27(1):121-127.
28. Nicolazzo J.A., Reed B.L., Finnin B.C. The effect of various in vitro conditions on the permeability characteristics of the buccal mucosa. J. Pharm. Sci. 2003, 92(12):2399-2410.
29. Lestari M.L., Nicolazzo J.A., Finnin B.C. A novel flow through diffusion cell for assessing drug transport across the buccal mucosa in vitro. J. Pharm. Sci. 2009, 98(12):4577-4588.
30. Blosi M., Albonetti S., Dondi M., Martelli C., Baldi G.v. Microwave-assisted polyolsynthesis of Cu nanoparticles. J. Nanopart. Res. 2011, 13:127-138.
31. Squier C.A., Wertz P.W., Cox P. Thin-layer chromatographic analyses of lipids in different layers of porcine epidermis and oral epithelium. Arch. Oral Biol. 1991, 36(9):647-653.
32. Huh C.H., Bhutani M.S., Farfán E.B., Bolch W.E. Individual variations in mucosa and total wall thickness in the stomach and rectum assessed via endoscopic ultrasound. Physiol. Meas. 2003, 24(4):N15-N22.
33. Bykov V.L. The tissue and cell defense mechanisms of the oral mucosa. Morfologiia 1996, 110(6):14-24.
34. Bykov V.L. The functional morphology of the epithelial barrier of the oral mucosa. Stomatologiia (Mosk.) 1997, 76(3):12-17. (review).
35. Abadi M.F., Mehrabian S., Asghari B., Namvar A.E., Ezzatifar F., Lari A.R. Silver nanoparticles as active ingredient used for alcohol-free mouthwash. GMS Hyg. Infect. Control 2013, 8(1). (Doc05). 10.3205/dgkh050002.
36. Bouadma L., Wolff M., Lucet J.C. Ventilator-associated pneumonia and its prevention. Curr. Opin. Infect. Dis. 2012, 25(4):395-404.
37. Kollef M.H., Afessa B., Anzueto A., Veremakis C., Kerr K.M., Margolis B.D., Craven D.E., Roberts P.R., Arroliga A.C., Hubmayr R.D., Restrepo M.I., Auger W.R., Schinner R. NASCENT investigation group. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008, 300(7):805-813.
38. Agarwala M., Barman T., Gogoi D., Choudhury B., Pal A.R., Yadav R.N. Highly effective antibiofilm coating of silver-polymer nanocomposite on polymeric medical devices deposited by one step plasma process. J. Biomed. Mater. Res. B: Appl. Biomater. 2014, 102(6):1223-1235.
39. Chakravarti A., Gangodawila S., Long M.J., Morris N.S., Blacklock A.R., Stickler D.J. An electrified catheter to resist encrustation by Proteus mirabilis biofilm. J. Urol. 2005, 174(3):1129-1132.
40. Shahare B., Yashpal M. Toxic effects of repeated oral exposure of silver nanoparticles on small intestine mucosa of mice. Toxicol. Mech. Methods 2013, 23(3):161-167.
41. Walczak A.P1., Fokkink R., Peters R., Tromp P., Herrera Rivera Z.E., Rietjens I.M., Hendriksen P.J., Bouwmeester H. Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology 2013, 7(7):1198-1210.
42. Holpuch A.S., Hummel G.J., Tong M., Seghi G.A., Pei P., Ma P., Mumper R.J., Mallery S.R. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm. Res. 2010, 27(7):1224-1236.
43. Hillyer J.F., Albrecht R.M. J. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. Pharm. Sci. 2001, 90(12):1927-1936.
44. Florence A.T. Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov. Today Technol. 2005, 2(1):75-81.
45. Hadrup N., Lam H.R. Oral toxicity of silver ions, silver nanoparticles and colloidal silver - a review. Regul. Toxicol. Pharmacol. 2014, 68(1):1-7.
46. Gaillet S., Rouanet J.M. Silver nanoparticles: their potential toxic effects after oral exposure and underlying mechanisms - a review. Food Chem. Toxicol. 2014, Dec 30. pii:S0278-6915(14)00530-4. 10.1016/j.fct.2014.12.019.
47. P.L. Drake, M.P.H., National Institute for Occupational Health and Safety; E. Pribitkin, M.D., Thomas Jefferson University; and W. Weber, N.D., Ph.D., M.P.H., NCCAM (July 2009). Colloidal Silver Products. U.S. Department of Health and Human Services.
48. "Colloidal Silver Not Approved", U.S. Food and Drug Administration, 2007 (retrieved 22.09.08).
49. "FDA Warning Letter", U.S. Food and Drug Administration, 2001 (retrieved 22.09.08).
50. "FDA Warning Letter", U.S. Food and Drug Administration, 2011 (retrieved 11.04.13).
51. Bianco C., Adami G., Crosera M., Larese F., Casarin S., Castagnoli C., Stella M., Maina G. Silver percutaneous absorption after exposure to silver nanoparticles: a comparison study of three human skin graft samples used for clinical applications. Burns 2014, 40(7):1390-1396.